• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    T.S. Vatseba, L.K. Sokolova


    About the author: T.S. Vatseba, L.K. Sokolova
    Type of article Scentific article
    Annotation Prevalence of breast cancer in the women with diabetes mellitus type 2 and the effect of hypoglycemic therapy on the frequency of the cancer and survival rates were studied. A significantly higher risk of breast cancer was detected in the women with type 2 diabetes mellitus [OR = 3.30; 95% CI (2.59-4.22) p<0.001]. Obesity and decompensation of diabetes are the factors of oncogenesis in patients with type 2 diabetes. The influence different types of hypoglycemic therapy on the frequency and survival rate of patients with breast cancer has not been proven. The higher risk of death from breast cancer to 5 years in people with diabetes mellitus type 2 compared with the patients without diabetes was revealed [OR = 4.80; 95% CI (2.96-7.81) p<0.001].
    Tags diabetes mellitus, cancer risk, breast cancer, survival rate of patients
    • Chernyshova AL,  Kolomiyets LA, Yunusova NV.  Patogeneticheskoye obosnovaniye neobkhodimosti korrektsii metabolicheskogo sindroma u bolnykh s giperplasticheskimi protsessami i rakom endometriya. Rossiyskiy bioterapevticheskiy zhurnal. 2013;(1):3–10. [in Russian]
    • Laktionov KP, Nikolayenko LO, Berishvili AI. Metabolicheskiy sindrom i rak organov reproduktivnoy sistemy. Opukholi zhenskoy reproduktivnoy sistemy. 2014;(2);56–58. [in Russian]
    • Misnikova IV. Sakharnyy diabet i rak. Rossiyskiy meditsinskiy zhurnal. 2016;20:1346-1350. [in Russian]
    • Nikitin YP, Openko TG, Simonova GI. Metabolicheskiy sindrom i yego komponenty kak vozmozhnyye modifitsiruyemyye faktory riska raka. Sibirskiy onkologicheskiy zhurnal. 2012;50:68–72.[in Russian]
    • Chang SC, Yang WCV. Hyperglycemia, tumorigenesis, and chronic inflammation. Crit Rev in Oncol/Hemat. 2016;(108):146-153. Doi: 10.1016/j.critrevonc.2016.11.003.
    • Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, D’Alessandro R, Orlandi A, Costarelli L, Cavaliere F, Guadagni F, Roselli M. Рretreatment insulin levels as a prognostic factor for breast cancer progression.Oncologist.2016;21(9):10411049.Doi:10.1634/theoncologist.2015-0462.
    • Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. A Cancer J for Clin. 2010; 60(4): 207–221. Doi: 10.3322/caac.20078.
    • Gristina V, Cupri MG, Torchio M, Mezzogori C, Cacciabue L, Danova M. Diabetes and cancer: А critical appraisal of the pathogenetic and therapeutic links. Biomed Rep.2015; 3(2): 131–136.
    • Jiménez  CG, Salmerón MG, Calvo AC, Martinez JMG, Castaño A, Vieja A. From obesity to diabetes and cancer: epidemiological links and role of therapies.Br J Cancer. 2016 Mar;114(7): 716–722. Doi: 10.1038/bjc.2016.37.
    • Joung KJ, Jeong JW, Ku BJ. Тhe association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int. 2015; Article ID 920618, 12 pages. Doi: 10.1155/2015/920618.
    • Kim J, Yang G, Kim Y, Kim J, Ha J.AMPK activators: mechanisms of action and physiological activities. Exp Mol Med. 2016;48(4): e224. Doi: 10.1038/emm.2016.16.
    • Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008; 109: 389–395.
    • Orgel E, Mittelman SD. Тhe links between insulin resistance, diabetes and cancer. Curr Diab Rep. 2013;13(2):213–222. Doi:10.1007/s11892-012-0356-6.
    • Rawłuszko-Wieczorek AA, Marczak Ł, Horst N, Horbacka K, Krokowicz P, Jagodziński PP. Significance of intratissue estrogen concentration coupled with estrogen receptors levels in colorectal cancer prognosis. Oncotarget. 2017;8(70):115546–115560. Doi: 10.18632/oncotarget.23309.
    • Sun XF, Shao YB, Liu MG, Chen Q, Liu ZJ, Xu B, Luo SX, Liu H. High-concentration glucose enhances invasion in invasive ductal breast carcinoma by promoting Glut1/MMP2/MMP9 axis expression. Oncol Lett. 2017 May;13(5):2989-2995. Doi: 10.3892/ol.2017.5843.
    Publication of the article «World of Medicine and Biology» №2(68), 2019 year, 030-034 pages, index UDK 618.19+616-006+616-056.36+616.379-008.64
    DOI 10.26724/2079-8334-2019-2-68-30-34